Stock analysts at Jefferies Financial Group started coverage on shares of Lava Therapeutics B.V. (NASDAQ:LVTX) in a research report issued on Monday, Analyst Price Targets reports. The firm set a “buy” rating and a $23.00 price target on the stock. Jefferies Financial Group’s target price points to a potential upside of 68.99% from the stock’s previous close.
Separately, SVB Leerink began coverage on Lava Therapeutics B.V. in a report on Monday. They issued an “outperform” rating and a $26.00 target price for the company.
LVTX stock opened at $13.61 on Monday. Lava Therapeutics B.V. has a twelve month low of $9.76 and a twelve month high of $17.20.
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia.
Featured Article: What is a growth and income fund?
Receive News & Ratings for Lava Therapeutics B.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lava Therapeutics B.V. and related companies with MarketBeat.com's FREE daily email newsletter.